This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Pharmaceutical Market: United Kindom

NEW YORK, March 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Pharmaceutical Market: United Kindom

http://www.reportlinker.com/p01117716/The-Pharmaceutical-Market-United-Kindom.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

Espicom market intelligence, brought to you by Business Monitor International

OVERVIEW OF THE PHARMACEUTICAL MARKET IN UNITED KINGDOM

Drugmakers and governments will increasingly enter agreements that provide some form of risk- sharing or price protection for new drugs. Since most European governments, including the UK authorities, are focussing on cost containment in the healthcare sector, alternative pricing schemes for medicines allow for budget control, as well as providing patients with access to highly innovative treatments. Guidance drafted by the National Institute for Health and Clinical Excellence (NICE) has recommended the use of Bristol-Myers Squibb 's Yervoy (ipilimumab) and Roche's Zelboraf ( vemurafenib) for the treatment of advanced skin cancer. These are the first new drugs approved for routine use by the UK's National Health Service for the disease in more than a decade. While this is positive news for both drugmakers, NICE's stamp of approval came only after the manufacturers of both drugs agreed to offer discounts, overturning a prior rejection of the treatments by the watchdog.

 

Headline Expenditure Projections:

Pharmaceuticals : GBP23.81bn ( US$38.33bn) in 2011 to GBP23.74bn ( US$37.27bn) in 2012; -0.3% in local currency terms and -2.8% in US dollar terms. Forecast unchanged from Q4 12.

Healthcare : GBP144.79bn ( US$232.99bn) in 2011 to GBP149.35bn ( US$234.48bn) in 2012; +3.2% in local currency terms and +0.6% in US dollar terms. Forecast unchanged from Q4 12.

Medical devices : GBP5.89bn ( US$9.48nn) in 2011 to GBP5.93bn ( US$9.30bn) in 2012; +0.6% in local currency terms and -1.9% in US dollar terms. Forecast unchanged from Q4 12.

 

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs